SCHEDULE: Dermata Therapeutics CFO Discloses Stake

Dermata Therapeutics CFO Kyri K. Van Hoose reports beneficial ownership of 9.0% of the company's common stock following a private placement and warrant amendments.

Summary

• Kyri K. Van Hoose, Chief Financial Officer and Senior Vice President of Dermata Therapeutics, Inc., has filed a Schedule 13D disclosing beneficial ownership of 384,352 shares of common stock, representing 9.0% of the outstanding shares.
• This ownership stake includes shares acquired in a private placement on December 23, 2025, and through amended warrants.
• The private placement involved the issuance of common stock, pre-funded warrants, Series C warrants, and Series D warrants.
• Van Hoose purchased 122,549 shares of common stock and warrants for an additional 245,098 shares.
• An existing warrant for 7,874 shares, originally issued on January 3, 2025, had its exercise price amended from $12.70 to $2.04.
• The source of funds for these acquisitions was personal funds.
• The reporting person acquired these securities for investment purposes and reserves the right to adjust their holdings or influence corporate activities.
• The filing date is May 27, 2026, with stockholder approval for warrant issuances obtained on the same date.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral to slightly negative. While it shows insider investment, the extensive warrant structure and the significant reduction in exercise price from a previous warrant raise concerns about potential future dilution and past valuation challenges.

Positives

• The CFO's investment demonstrates personal confidence in the company's future prospects.
• The acquisition of shares and warrants in a private placement suggests ongoing capital infusion and investor interest.
• The amendment of a warrant exercise price to a lower, more accessible level ($2.04) could facilitate future share conversions.

Negatives

• The significant number of warrants and pre-funded warrants outstanding could lead to substantial dilution for existing shareholders upon exercise.
• The original exercise price of $12.70 for a portion of the warrants indicates a substantial decrease in the perceived value of the stock since that time.

Risks

• Potential for significant dilution of existing shareholders' equity due to the exercise of a large number of warrants and pre-funded warrants.
• The reporting person, in their executive capacity, may influence corporate activities, which could align with personal investment goals rather than all shareholder interests.
• The company's reliance on private placements and warrant structures may indicate challenges in accessing traditional forms of capital or a need for ongoing funding.

Future Outlook

The reporting person reserves the right to acquire or dispose of additional securities, or to formulate other plans or proposals regarding the Issuer, depending on market conditions and other factors. This indicates flexibility and potential for future strategic actions.

Management Comments

• The Reporting Person acquired the securities reported herein for investment purposes.
• The Reporting Person reserves the right to acquire, or cause to be acquired, additional securities of the Issuer, to dispose of, or cause to be disposed of, such securities at any time or to formulate other purposes, plans or proposals regarding the Issuer or any of its securities, to the extent deemed advisable in light of general investment and trading policies of the Reporting Person, market conditions or other factors.
• The Reporting Person serves as Chief Financial Officer of the Issuer, and in such capacity, may have influence over the corporate activities of the Issuer.

Industry Context

StockSavvy.ai notes that Schedule 13D filings by company insiders, particularly C-suite executives like CFOs, often signal significant personal investment and potential strategic influence. The details of this private placement and warrant structure are common in biotechnology and early-stage companies seeking capital, but the significant number of warrants warrants close monitoring for potential dilution.

Stakeholder Impact

• Shareholders may experience dilution in their ownership percentage due to the exercise of a large number of warrants and pre-funded warrants.
• Employees may be impacted by potential future capital raises or strategic shifts influenced by the reporting person.
• Creditors could be affected by changes in the company's financial structure or performance resulting from the reporting person's potential influence.

Next Steps

• The reporting person may acquire or dispose of additional securities.
• The reporting person may formulate new plans or proposals regarding the Issuer.
• Warrants are exercisable upon stockholder approval, which has been obtained.
• Series C Warrants expire five years from the effective date of stockholder approval.
• Series D Warrants expire twenty-four months from the effective date of stockholder approval.

Key Dates

Recommendation

The filing indicates significant insider investment and a completed private placement, which are generally positive. However, the substantial number of outstanding warrants and the reduced exercise price compared to a previous warrant issuance raise concerns about future dilution and the company's valuation trajectory. A 'hold' recommendation is appropriate pending further clarity on the company's operational progress and the impact of warrant exercises.

Keywords

Schedule 13D, Dermata Therapeutics, Kyri K. Van Hoose, Beneficial Ownership, Common Stock, Warrants, Private Placement, Securities Purchase Agreement, CFO, SEC Filing